The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Percutaneous radiofrequency ablation of renal cancer.
It replaces the previous guidance on Percutaneous radiofrequency ablation of renal cancer (NICE interventional procedure guidance 91, September 2004).
Renal cancer is cancer of the kidney. Percutaneous radiofrequency ablation of renal cancer involves placing one or more electrode-needles through the skin into the kidney. The electrodes are placed within the tumour and produce heat, with the aim of destroying the cancer cells.
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.